🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Sichuan Huiyu Pharmaceutical clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Sichuan Huiyu Pharmaceutical as lead sponsor. Synced 26 Sep 2026
9Current trials
9Recruiting now
2Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Sichuan Huiyu Pharmaceutical is the lead sponsor of 9 current clinical trials in our China register. 9 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are Ferric Carboxymaltose and Ferric Derisomaltose. The most-studied condition is Solid Tumor.

ClinicalTrials.gov trials by status

  • Recruiting9100%

Trials by phase

  • Phase 1/2556%
  • Phase 1333%
  • Not applicable111%
01

Clinical trials sponsored by Sichuan Huiyu Pharmaceutical

9 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes
NCT06712680 · ClinicalTrials.gov ↗ · Solid Tumor
Phase 1/2 Recruiting 2024-11 China
Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer
NCT06765590 · ClinicalTrials.gov ↗ · Breast Cancer
Not applicable Recruiting 2025-03 China
A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation
NCT06756490 · ClinicalTrials.gov ↗ · Moderate or Severe Submental Fullness
Phase 1 Recruiting 2024-12 China
A Study of Ferric Derisomaltose Injection in Chinese Participants With Iron Deficiency Anemia Under Fasting Conditions
NCT07790562 · ClinicalTrials.gov ↗ · Iron Deficiency Anemia
Phase 1 Recruiting 2026-07 China
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
NCT06243354 · ClinicalTrials.gov ↗ · Safety, Tolerability, Efficacy
Phase 1/2 Recruiting 2024-02 China
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
NCT07083323 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1/2 Recruiting 2025-07 China
A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors
NCT07069062 · ClinicalTrials.gov ↗ · Solid Tumor
Phase 1/2 Recruiting 2025-07 China
Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants Under Fasting Conditions
NCT07606105 · ClinicalTrials.gov ↗ · Healthy Adult
Phase 1 Recruiting 2026-05 China
Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors
NCT06639256 · ClinicalTrials.gov ↗ · Safety, Tolerability, Efficacy
Phase 1/2 Recruiting 2024-10 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Sichuan Huiyu Pharmaceutical trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Sichuan Huiyu Pharmaceutical trials

9 conditions
Solid Tumor2Safety2Tolerability2Efficacy2Breast Cancer1Moderate or Severe Submental Fullness1Iron Deficiency Anemia1Advanced Solid Tumor1Healthy Adult1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China99

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Solid Tumor

SponsorTrials
Sichuan Baili Pharmaceutical23
Suzhou Suncadia Biopharmaceuticals4
Peking University Cancer Hospital & Institute3
Chinese PLA General Hospital3
Shenzhen Geno-Immune Medical Institute3
Shanghai Cell Therapy Group3
Hua Zhu3
Pyxis Oncology2
Tyra Biosciences2
Biohaven Therapeutics2

Sponsors with the most current trials registered for this condition.

06

Questions about Sichuan Huiyu Pharmaceutical trials

How many clinical trials does Sichuan Huiyu Pharmaceutical sponsor?

Sichuan Huiyu Pharmaceutical is the lead sponsor of 9 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Sichuan Huiyu Pharmaceutical trials recruiting?

Yes. 9 of its 9 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Sichuan Huiyu Pharmaceutical testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Ferric Carboxymaltose (1) and Ferric Derisomaltose (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.